AlphAIAlphAI — Financial news for AI agents
investing.comOCT 122 min read$JNJ

J&J reports three-year tremfya data for Crohn’s disease

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

Original reporting
investing.com
Published Oct 12, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial results are a primary disclosure that could shift investor sentiment and valuation for JNJ's immunology franchise.

02

Market read

New efficacy data may drive short‑term buying interest in JNJ and influence peer biotech stocks.

03

What to watch

Potential reimbursement challenges and competition from other IL‑23 inhibitors could limit upside.

Relevance 7/10Novelty 8/10Timing: same-day release

Background

The article reports Johnson & Johnson's first public release of long‑term extension data for its Crohn's disease therapy TREMFYA.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson disclosed three-year Phase 3 GALAXI 2/3 trial results for TREMFYA in Crohn's disease, showing high remission rates.

Expected impact

likely upward pressure as the market prices in the strong efficacy outcomes

Evidence & confidence

The data are new, material, and improve the drug's commercial outlook, which historically moves JNJ stock on similar announcements.

Market effects

Sector

Strengthens the biotech/IBD therapeutic segment and may boost peer valuations in the inflammatory‑disease space.

Regional

U.S. and European markets may see modest gains in pharma stocks following the announcement.

Global

Adds to the pipeline credibility of large diversified pharma firms globally.

Counterpoint

What could challenge this read

If the market has already priced in optimism for TREMFYA, the data may be a disappointment relative to expectations.

Key entities

  • company
    Johnson & Johnson

    US‑listed diversified health‑care conglomerate

  • drug
    TREMFYA (guselkumab)

    IL‑23 inhibitor approved for Crohn's disease

Read at source← All news

StoryJohnson & Johnson reports three‑year remission rates for TREMFYA in Crohn’s disease

Related articles

OCT 12
$JNJMed

Johnson & Johnson's Tremfya Shows Promising Long-Term Remission

Johnson & Johnson (JNJ) reported that its drug Tremfya achieved 94% clinical remission in Crohn’s disease patients over three years in phase 3 trials. JNJ has a 1.95% dividend yield, 55% payout ratio, and 4.9% 3-year dividend growth. The stock is 35.7% above its GF Value of $194.33, trading at $263.73. JNJ has a GF Score of 83, indicating strong financial health, but insiders have been net sellers.

gurufocus.com3 min
OCT 12
$JNJHigh

Johnson & Johnson Announces New Three-Year Data From Phase 3 GALAXI 2 And 3 Studies Showing Durable Efficacy And A Consistent Safety Profile for TREMFYA

Johnson & Johnson presented three-year data from Phase 3 GALAXI 2 and 3 studies, showing durable efficacy and consistent safety for TREMFYA in Crohn's disease. Results indicate high rates of clinical and endoscopic remission for both dosing regimens. TREMFYA is approved for Crohn's disease and other inflammatory conditions.

marketscreener.com2 min
OCT 12
$JNJMed

Johnson & Johnson Announces New Phase 3 Data Showing Consistent Combined Fistula Remission Outcomes With TREMFYA Across Clinically Important Subgroups Of Adults With Crohn's Disease With Perianal Fistula

Johnson & Johnson reported Phase 3 data showing TREMFYA achieved 28% and 27% combined fistula remission in Crohn's disease patients, vs. 10% for placebo. Subgroup analyses showed consistent results across different patient types. The study was presented at the ACG 2026 meeting.

marketscreener.com2 min
OCT 12
$JNJMedAI 9/10

J&J’s Tremfya shows fistula remission in Crohn’s subgroups

Johnson & Johnson (JNJ) reported Phase 3 data showing Tremfya achieved 28% and 27% fistula remission in Crohn's patients at Week 24, versus 10% for placebo. Subgroup analyses showed higher remission rates in specific patient groups. Tremfya is approved for Crohn's disease in the U.S. The data was presented at the American College of Gastroenterology 2026 meeting.

investing.com2 min
OCT 12
$JNJMedAI 9/10

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Johnson & Johnson announced Phase 3 data showing TREMFYA (guselkumab) achieved consistent combined fistula remission rates in Crohn's disease patients with perianal fistula, including difficult-to-treat subgroups. Remission rates were 28% and 27% for two dosing groups vs. 10% for placebo. Results were presented at the ACG 2026 Annual Scientific Meeting.

prnewswire.com2 min